<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NISOLDIPINE</span><br/>(ni-sol'di-peen)<br/><span class="topboxtradename">Nisocor, </span><span class="topboxtradename">Sular<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">calcium channel blocker</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Nifedipine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg, 30 mg, 40 mg sustained release tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Structurally similar to nifedipine. Inhibits calcium ion influx across cell membranes of cardiac muscle and vascular smooth
         muscle, which results in vasodilation, inotropism, and negative chronotropism.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits vasoconstriction in the peripheral vasculature (10 times as potent than nifedipine). Significantly reduces total
         peripheral resistance, decreases blood pressure, and increases cardiac output. It is also a potent coronary vasodilator.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypertension, angina.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>CHF.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to nisoldipine or other calcium blockers; systolic BP 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Liver dysfunction; older adult; paroxysmal atrial fibrillation; digital ischemia, ulceration, or gangrene; nonobstructive
         hypertrophic cardiomyopathy; Duchenne muscular dystrophy; lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension, Angina</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1020 mg/d in 2 divided doses (max: 40 mg/d), may need to reduce dose in patients with liver disease (cirrhosis, chronic
               hepatitis)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug with food to decrease GI distress, but do not give with grapefruit juice or a high fat meal.</li>
<li>Ensure that sustained release form is not chewed or crushed. It must be swallowed whole.</li>
<li>Discontinue drug gradually to prevent adverse effects.</li>
<li>Consider dosage reductions in older adults; initiate therapy at lower doses and follow with gradual increases.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, anxiety, tremor, weakness, fatigue, <span class="speceff-common">headache.</span> <span class="typehead">CV:</span> Hypotension, lower extremity edema, palpitations, orthostatic hypotension. <span class="typehead">GI:</span> Abdominal pain, cramps, constipation, dry mouth, diarrhea, nausea. <span class="typehead">Skin:</span> <span class="speceff-common">Flushing,</span> rash, erythema, urticaria. <span class="typehead"> Urogenital:</span> Urinary frequency. <span class="typehead">Respiratory:</span> Pulmonary edema (patients with CHF), wheezing, dyspnea. <span class="typehead">Body as a Whole:</span> Myalgia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May cause significant increase in <b>digoxin</b> level in patients with CHF. <span class="classification">beta blockers</span> may cause hypotension and bradycardia. <b>Phenytoin</b> may significantly decrease nisoldipine levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract; 48% reaches systemic circulation; absorption not affected by food. <span class="typehead">Peak Effect:</span> 13 h. <span class="typehead">Duration:</span> 812 h for hypertension, 78 h for angina. <span class="typehead">Distribution:</span> 99% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized in liver. <span class="typehead">Elimination:</span> 7075% excreted in urine as metabolites. <span class="typehead">Half-Life:</span> 214 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor blood pressure carefully during period of drug initiation and with dosage increments.</li>
<li>Monitor cardiovascular status especially heart rate, frequency of angina attacks, or worsening heart failure.</li>
<li>Assess for and report edematous weight gain.</li>
<li>Monitor digoxin levels closely with concurrent use and watch for S&amp;S of digoxin toxicity (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not discontinue the drug abruptly.</li>
<li>Report symptoms of orthostatic hypotension or other bothersome adverse effects to physician.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>